该集团积极推动研发项目进展，研发投入占营业收入比例持续上升。报告期内集团研发投入约人民币 3.58 亿元。其中：治疗三阴乳腺癌的 FDA018 抗体偶联剂(即抗 Trop2 抗体偶联 SN38 项目)III期临床试 验入组工作较塬计划提前完成，累计入组人数超 350 例，目前该项目数据结果正在收集统计中，集团将 尽快递交上市申请;针对人表皮生长因子受体 2(HER2)低表达乳腺癌适应症的 FDA022 抗体偶联剂(即抗 Her2 抗体偶联 BB05 项目)II 期临床研究入组结束，并于报告期内完成与监管方的临床学科沟通会 (EOP2 会议)。集团全资子公司泰州复旦张江药业有限公司于报告期内持续为集团抗体偶联药物(ADC) 研发项目的产业化提供支持，先后开展商业化规模的生产技术转移、生产工艺验证及后期试验样品生产 等工作。此外，集团光动力药物研发项目按计划稳步推进，其中：盐酸氨酮戊酸口服溶液用粉末用于高 级别脑胶质瘤术中可视化项目药品注册上市许可申请已获受理。 报告期内，集团生产经营正常，主要上市销售药品种类未发生变化。由于盐酸多柔比星脂质体注射液被 纳入国家集采目录，公司产品里葆多®未获中选，依据相关集采规则 ...

Core Viewpoint - Fudan Zhangjiang (01349) experienced a nearly 3% decline in stock price following the announcement of its mid-year results for 2025, reflecting a decrease in revenue and profit [1] Financial Performance - The company reported revenue of approximately 390 million yuan, representing a year-on-year decrease of 4.42% [1] - Shareholder profit attributable to the company was 5.715 million yuan, a significant year-on-year decline of 91.89% [1] - Earnings per share were reported at 0.0055 yuan [1] Reasons for Profit Decline - The decline in profit was primarily attributed to an increase in research and development expenses compared to the same period last year [1] - The previous year's results included compensation and penalties related to the termination of cooperation with the promotional service provider, Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. [1]

Group 1 - Fudan Zhangjiang reported a revenue of 390 million yuan for the first half of 2025, a year-on-year decrease of 4.42%, and a net profit attributable to shareholders of 5.71 million yuan, down 91.89% year-on-year [1] - The company maintained a high R&D investment of 178 million yuan, which represents 45.63% of its revenue, an increase of 7.57% year-on-year [1] - The company is a leader in photodynamic therapy, with ongoing research expanding indications for its products, including treatments for cervical diseases and acne, which have completed Phase II clinical trials [1] Group 2 - The ADC technology platform is accelerating clinical trials, with ongoing Phase III trials for the anti-Trop2 antibody conjugate SN38 for triple-negative breast cancer and other tumor types [2] - Fudan Zhangjiang's production base in Taizhou is capable of large-scale commercial production for the F0024 project, supporting the ongoing Phase III clinical trial [2] - The company has completed technology transfer for the F0034 project, which is also preparing for Phase III clinical trial sample production [2] Group 3 - Due to not winning the bid for the tenth batch of national procurement, Fudan Zhangjiang has implemented a gradual price reduction for the product Libao Duo starting May 1, 2025, which may impact short-term revenue [3] - Despite short-term performance fluctuations, the company remains committed to innovation and R&D in photodynamic and ADC technology, aiming to drive long-term value [3] - As the pipeline gradually moves towards commercialization, Fudan Zhangjiang is expected to strengthen its position in the innovative drug sector [3]

Core Viewpoint - Fudan Zhangjiang (01349) reported a decline in revenue and profit for the first half of 2025, primarily due to increased R&D expenses and the impact of a previous partnership termination with a service provider [1] Financial Performance - Revenue for the period was approximately 390 million yuan, representing a year-on-year decrease of 4.42% [1] - Shareholders' profit amounted to 5.715 million yuan, reflecting a significant year-on-year decline of 91.89% [1] - Earnings per share were reported at 0.0055 yuan [1] Factors Influencing Performance - The decline in profit was attributed to an increase in R&D expenses compared to the same period last year [1] - The previous year's termination of cooperation with the promotional service provider, Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd., led to the recognition of corresponding compensation and penalty fees [1]

Core Viewpoint - Fudan Zhangjiang (688505.SH) reported a significant decline in both revenue and net profit for the first half of 2025, primarily due to increased R&D expenses and the absence of compensation income from a terminated partnership with Shanghai Huizheng [1] Financial Performance - The company achieved revenue of 390 million yuan, a year-on-year decrease of 4.42% [1] - Net profit attributable to shareholders was 5.72 million yuan, reflecting a year-on-year decline of 91.89% [1] - The company reported a non-recurring net profit loss of 9.49 million yuan, indicating a shift from profit to loss compared to the previous year [1] - Basic earnings per share were 0.01 yuan [1] R&D and Operational Changes - The decline in key financial metrics was significantly influenced by an increase in R&D expenses compared to the same period last year [1] - The previous year's financials included compensation and penalties from the termination of the partnership with the promotional service provider for the product Li Baoduo®, which did not recur in the current reporting period [1]

Core Viewpoint - Fudan Zhangjiang reported a significant decline in both revenue and net profit for the first half of the year, primarily due to increased R&D expenses and the absence of compensation from a previous partnership [1] Financial Performance - The company achieved a revenue of 390 million yuan, representing a year-on-year decrease of 4.42% [1] - The net profit attributable to shareholders was 5.71 million yuan, down 91.89% from 70.47 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.01 yuan [1] Factors Influencing Performance - The decline in financial metrics was mainly attributed to an increase in R&D expenses compared to the previous year [1] - The previous year's financials included compensation and penalties from the termination of a partnership with Shanghai Huizheng, which did not recur in the current reporting period [1]